Clinical Trials Browser

Multiple Myeloma

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Urinary Bladder Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms

Adenomatous Polyps

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Pancreatic Neoplasms

Esophageal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Recurrence

Glioblastoma

Hodgkin Disease

Carcinoma, Non-Small-Cell Lung

Neuroblastoma, Osteosarcoma

Neoplastic Cells, Circulating, Prostatic Neoplasms

Cytokine Release Syndrome, Bronchiolitis Obliterans Syndrome, Neoplasms

Alzheimer Disease, Lymphoma, Neoplasms, Plasma Cell

Melanoma, Neoplasms

Cachexia, Digestive System Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Central Nervous System Venous Angioma

Breast Neoplasms, Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Fibrosis, Carcinoma, Hepatocellular, Liver Neoplasms

Prostatic Neoplasms

Ovarian Neoplasms

Colorectal Neoplasms

Skin Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Carcinoma, Squamous Cell, Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Hemangioma, Hemangioma, Capillary, Vascular Malformations

Carcinoma, Renal Cell, Neoplasms

Breast Neoplasms

Astrocytoma, Glioblastoma, Glioma

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplastic Cells, Circulating

Urinary Bladder Neoplasms

Obesity, Multiple Endocrine Neoplasia Type 1, Atherosclerosis

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Clinical Trials

Gemcitabine and Docetaxel With Radiation in Adults With Soft Tissue Sarcoma of the Extremities

AMBROBiMM

PAIR HPV

The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery

PARTICLE-PATHY

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

FIT

LUTON

Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy

Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence

MINDACTRelapse

IMMUNOPBMC

Bioenergetic Profiling and Cognition in GBM Patients

REVOLUMHOD

Use Peripheral Blood Proteomics to Predict the Treatment Response and Toxicities in NSCLC Immunotherapy

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

CHARTER

FRACTal

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

ELICIT

PET Imaging of Subjects Using 124I-PU-AD

REPOSIT

Sample Collection From Melanoma Patients

MYOCAC

Memory Phenotype and PD-1 Inhibition Response in Oral Cancer

Explor-AVD

Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer

Metabolic and Microbial Profiling of Lung Cancer

PALTAN

Characterization of Methylation Patterns in Hepatocellular Carcinoma

Circulating Tumor Cells in Prostate Cancer Patients

Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis

DPD côlon

BACCHUS

Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma

Identification of Key Blood Molecular Markers for Immunotherapy

Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery

CPCT-01

Genetic Basis of Hemangiomas

Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma

Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer

Gliomstudien

Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)

CIRCUBRONCH

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like Angina

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers